• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to a process for purifying factor VII and/or activated factor VIIa (F VII/F VIIa) by means of binding to immobilized soluble thromboplastin.
    公开号:US20010007901A1
    申请号:US09/768,294
    申请日:2001-01-25
    公开日:2001-07-12
    发明作者:Jurgen Romisch；Hans-Arnold Stohr；Annette Feussner
    申请人:Aventis Behring GmbH；
    IPC主号:C12N9-6437
    专利说明:
    [0001] The invention relates to a process for purifying factor VII and/or activated factor VII (F VII/F VIIa) by means of binding to immobilized soluble thromboplastin. [0001]
    [0002] Coagulation factor VII (FVII) constitutes, together with thromboplastin (tissue factor, TF), the complex which initiates the extrinsic coagulation pathway. When tissue injury occurs, TF is exposed, enabling FVII and/or FVIIa to bind to its extracellular protein domain. A hydrophobic protein region anchors TF in the membrane. [0002]
    [0003] In the presence of (preferably negatively charged) lipids and calcium, the physiologically active component of the FVII/FVIIa mixture, namely TF-FVIIa, efficiently activates factor X (FX). FXa in turn (together with FVa, lipids and calcium) catalyzes the generation of thrombin. The subsequent formation of fibrin ensures wound closure, inter alia. [0003]
    [0004] FVII which is bound to membrane-located TF is in turn activated by autoactivation (mediated by TF-FVIIa) or by FIXa, FXa and thrombin, thereby further amplifying the cascade-like activation of the coagulation system. [0004]
    [0005] Correspondingly, a deficiency of FVII can be associated with hemostatic complications such as a tendency to hemorrhages. As a coagulation factor whose synthesis to form the physiologically functional molecule depends on the presence of vitamin K, complications can correspondingly arise, for example in association with oral anticoagulation (with vitamin K antagonists) before operations; consumption coagulopathies and liver damage represent additional indications for providing FVII replacement therapy. FVIIa, on the other hand, is a constituent of activated PPSB preparations which can be used in association with acute hemorrhages. In addition to this, FVIIa possesses a so-called factor VIII-bypassing activity which is used when providing replacement therapy to hemophilliacs who are suffering, for example, from FVIII intolerance (e.g. antibodies). [0005]
    [0006] FVII/FVIIa is normally concentrated from plasma or culture supernatants (in the case of recombinant preparation) using several preparation steps, a procedure which is usually associated with corresponding losses of yield. As a protein which is related both structurally and in its properties to other coagulation factors, its purification from a corresponding mixture is both difficult and elaborate. In addition to this, there is the danger, in the case of FVII, that, as the purification process becomes more elaborate, an activation (to FVIIa) will occur which (in conformity with the sought-after preparations) must be avoided. Preparations using suitable immobilized monoclonal antibodies represent examples of rapid methods. Usually, however, elution conditions are required (pH 3 - pH4) which damage the protein irreversibly. Partial denaturation results in corresponding losses of yield and can also cause the conformationally altered molecular structures to become antigenic. [0006]
    [0007] The underlying object of the present invention is therefore to provide a process for the rapid and mild purification of FVII/FVIIa. [0007]
    [0008] The object was achieved as follows: FVII and/or FVIIa are removed from an FVII/FVIIa-containing solution by binding them to an immobilized sTF (“soluble” thromboplastin, soluble tissue factor), unbound molecules are removed from the matrix by washing and FVII/FVIIa is subsequently eluted under mild conditions. In this context, sTF is thromboplastin which lacks the transmembrane moiety and the cytoplasmic moiety and is consequently the extracellular domain of TF. [0008]
    [0009] We have found that the interaction of FVII/FVIIa with sTF can be utilized to purify FVII and/or FVIIa. Thus, whereas the “physiological” complete (lipid-binding) TF brings about autoactivation and proteolysis or feedback activation of the bound FVII by FIXa, FXa and thrombin, FVII which is bound to sTF remains unaffected (Morrissey; Thromb. Haemostas. 1995; 74:185-188). [0009]
    [0010] The binding of FVII and/or FVIIa to sTF is optimized in the presence of doubly charged ions, particularly by calcium, whereas other proteins can be removed in unbound form. Accordingly, an immobilized sTF is adsorbed to a matrix, FVII and/or FVIIa are, in the presence of calcium, bound to sTF from out of a solution and unbound molecules are removed from the solid phase by washing. The elution is carried out in a mild manner using a buffer which contains a chelating agent such as citrate, oxalate, tartrate, EDTA or the like. [0010]
    [0011] The sTF can be adsorbed to a solid phase by way of non-covalent bonding or be immobilized by means of covalent bonding. Suitable binding partners are conventionally prepared sTF (prepared proteolytically from complete TF), recombinantly prepared sTF or FVII/FVIIa-binding moieties (peptide regions from sTF). The sTF, or appropriate FVII-binding regions, can be coupled to substances which simplify or optimize immobilization (e.g. as a spacer function, see below). [0011]
    [0012] In a preferred approach, an sTF (Fc-sTF) which is coupled to an Fc fragment is used, as described in EP 464533 (Lauffer et al). The sTF is optimally presented, and the efficiency of the purification system is increased, by, for example, binding the Fc-sTF to an anti-Fc column or to a protein A matrix or protein G matrix. Since samples which contain Fc fragments or immunoglobulins can lead to displacement of the Fc-sTF from the matrix, it is advisable to couple the Fc-sTF covalently to the matrix using known methods. [0012]
    [0013] Doubly charged ions, preferably calcium, preferably in the form of CaCl[0013] 2, at a concentration of from 0.01 to 500 mM, particularly preferably of from 0.5 to 50 mM, are added to the FVII/FVIIa-containing solution. The solution should have a pH of from 5.0 to 10.0, preferably of from 7.0 to 9.5. This solution is brought into contact with the sTF-matrix and the matrix is washed with a buffer solution which preferably has a pH of between 7.0 and 9.5 and a calcium concentration of between 0.5 and 50 mM. Elution is effected using a solution which contains a chelating agent, preferably citrate, oxalate, tartrate, NTA, EDTA or EGTA, in concentrations of 0.1-1000 mM, preferably between 5 and 200 mM. The solution has a pH of from 5.0 to 10.0, preferably of from 5.5 to 8.5, particularly preferably of from 6.0 to 7.5.
    [0014] Samples which contain activated factors can give rise to additional generation of FVIIa (possibly from the excess of factor VII which is present) and consequently to artificial results. In order to avoid this risk, antithrombin III/heparin can be added to the sample before contact with the immobilized sTF. Since FVIIa is only inhibited slowly by ATIII/Hep. at room temperature or at higher temperatures in comparison to other, potentially interfering factors (FIIa, FIXa, FXa, etc.), the latter can be blocked, without having a significant effect on the content of FVIIa, if the intention is to purify FVIIa. TF-bound FVIIa can sometimes be inhibited more efficiently by ATIII/Hep. than are the free molecules (however, without functional heparin, ATIII reacts only very slowly, in analogy with soluble FVIIa). Therefore, the heparin which is added can be neutralized with known reagents such as protamine sulfate/Polybren® prior to contact with sTF, with the subsequent procedure being as described above. [0014]
    [0015] Reversible inhibitors, e.g. benzamidine, and other cofactor-dependent inhibitors which themselves, or their accelerators, can be neutralized (for example heparin-cofactor II/heparin) are also suitable for this step of the process. [0015]
    [0016] The invention is explained in more detail by the following example: [0016] EXAMPLE
    [0017] Protein A-Sepharose was loaded with Fc-sTF (10 μg/50 μl of gel matrix) and equilibrated with buffer A (50 mM tris/HCl, 150 mM NaCl, 10 mM CaCl[0017] 2, 0.1% human albumin, pH: 8.5). FVIIa was added to 0.5 ml of a protein solution which contained FVII (15 IU/ml) to a concentration which corresponded to 5% (in a coagulation test) of the FVII activity. The solution also contained other coagulation factors such as factors II (30 IU/ml), IX (25 IU/ml) and X (30 IU/ml), as well as a number of additional plasma proteins. This solution was diluted with an equal volume of buffer A and brought into contact with the sTF-matrix in a small column. After the flow-through had passed through the column, the matrix was washed with 0.5 ml of buffer A and bound protein was subsequently eluted with buffer B (50 mM tris/HCl, 150 mM NaCl, 50 mM sodium citrate, pH 6.5), and collected.
    [0018] The eluate was tested in appropriate coagulation tests and the yield of FVII/VIIa was quantified (in relation to the starting material) by its activity and also by means of ELISA. The purity of the eluate was demonstrated by SDS-PAGE. [0018] RESULT
    [0019] The yield of FVII/FVIIa was 93% by ELISA and 90% by activity, based on the starting material. Another important finding was that, once again, 5% of the FVII activity in the eluate derived from (the added) FVIIa. This demonstrates that neither of the two molecules was bound preferentially. On the other hand, the possibility can be excluded that activation of FVII to FVIIa took place during this purification step. [0019]
    [0020] While neither FII, FIX nor FX was found in the eluate, they were all found (in correspondence with the starting material) in the column flow-through. The purity of the eluate, and the powerful effect in concentrating FVII/VIIa in the eluate, is clearly shown by SDS-PAGE analysis, which convincingly demonstrates the purification effect. [0020]
    权利要求:
    Claims (9)
    [1" id="US-20010007901-A1-CLM-00001] 1. A process for purifying factor VII and/or factor VIIa, which comprises removing factor VII and/or factor VIIa from a factor VII and/or factor VIIa-containing solution by binding them to immobilized soluble thromboplastin, removing unbound molecules by washing, and eluting the bound factor VII and/or factor VIIa.
    [2" id="US-20010007901-A1-CLM-00002] 2. The process as claimed in
    claim 1 , wherein bound factor VII and/or factor VIIa is eluted using a chelating agent.
    [3" id="US-20010007901-A1-CLM-00003] 3. The process as claimed in
    claim 1 or
    claim 3 , wherein Ca2+ions are added at a concentration of between 0.01 and 500 mM, and a pH of 5.0 - 10.0 is selected in association with the binding to immobilized soluble thromboplastin.
    [4" id="US-20010007901-A1-CLM-00004] 4. The process as claimed in
    claim 2 or
    claim 3 , wherein citrate, oxalate, tartrate, NTA, EDTA or EGTA, at a concentration of 0.1 - 1000 mM, which is sufficient to elute factor VII and/or factor VIIa, is selected as the chelating agent.
    [5" id="US-20010007901-A1-CLM-00005] 5. The process as claimed in one of the preceding claims, wherein other, interfering activated factors are inhibited prior to the contact with immobilized soluble thromboplastin.
    [6" id="US-20010007901-A1-CLM-00006] 6. The process as claimed in
    claim 5 , wherein, prior to the contact with immobilized soluble thromboplastin, other, potentially interfering activated factors are inactivated by adding antithrombin III/heparin, and protamine sulfate is subsequently added, where appropriate.
    [7" id="US-20010007901-A1-CLM-00007] 7. The process as claimed in one of the preceding claims, wherein soluble thromboplastin is adsorbed to the solid phase by way of non-covalent bonding.
    [8" id="US-20010007901-A1-CLM-00008] 8. The process as claimed in
    claim 7 , wherein a soluble thromboplastin is employed which is coupled to an Fc fragment.
    [9" id="US-20010007901-A1-CLM-00009] 9. The process as claimed in
    claim 1 to
    claim 6 , wherein soluble thromboplastin is covalently bonded to the solid phase.
    类似技术:
    公开号 | 公开日 | 专利标题
    US6573056B2|2003-06-03|Process for purifying factor VII and activated factor VII
    EP0197901B1|1991-07-24|Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations
    Kannemeier et al.2001|Factor VII and single‐chain plasminogen activator‐activating protease: activation and autoactivation of the proenzyme
    JP3735112B2|2006-01-18|Antibodies specific for clotting proteins, their use to isolate native proteins, clotting compositions free of proteolytic cleavage products of the proteins
    EP0182372A2|1986-05-28|New factor VIII coagulant polypeptides
    EP0123945B1|1996-03-13|New factor VIII coagulant polypeptides
    Takebe et al.1995|Calcium ion-dependent monoclonal antibody against human fibrinogen: preparation, characterization, and application to fibrinogen purification
    JP2000023696A|2000-01-25|Protease for activating clotting factor vii
    HUT72712A|1996-05-28|Purification of factor vii
    WO1992007584A1|1992-05-14|Pharmaceutical preparation for the treatment of prolonged coagulation time
    EP0162078B1|1994-09-14|Method for isolating a protein from a mixture containing said protein and a conformation specific antibody useful therein
    JP2001095563A|2001-04-10|Preparation of protease activating blood coagulation factor vii, its proenzyme or mixture of both proteins in purified state by ion exchange chromatography
    WO1996013274A1|1996-05-09|Process for production of inhibited forms of activated blood factors
    JP2824430B2|1998-11-11|Method for preparing blood coagulation factor VII or activated blood coagulation factor VII
    AU9244998A|1999-04-12|Pharmaceutical substance containing various vitamin k-dependent factors
    Mitchell et al.1988|Inhibition of the anticoagulant activity of protein S by prothrombin.
    JP4180671B2|2008-11-12|Protein preparation and recovery methods
    JPH1075778A|1998-03-24|Peptide bonding with prothrombin and thrombin
    Dempfle et al.1987|Purification of human plasma fibrinogen by chromatography on protamine-agarose
    EP3817765A1|2021-05-12|Fx activation process and its use in the preparation of a fxa composition
    US5047506A|1991-09-10|Method for the purification of factor XIII by affinity chromatography
    US6835817B2|2004-12-28|Monoclonal antibody which is specific for activated coagulation factor VII, and its use
    AU781717B2|2005-06-09|Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or mixture of both proteins by means of ion-exchange chromatography
    Clement1983|Purification and Characterization of Guinea PIG Anti Thrombin III
    同族专利:
    公开号 | 公开日
    CA2188093A1|1997-04-19|
    AU706057B2|1999-06-10|
    JP3963406B2|2007-08-22|
    KR970021093A|1997-05-28|
    JPH09165397A|1997-06-24|
    CA2188093C|2007-04-24|
    EP0770625B1|2002-07-24|
    AT221085T|2002-08-15|
    KR100457984B1|2005-01-31|
    AU7022696A|1997-04-24|
    EP0770625A3|1998-07-08|
    ES2180680T3|2003-02-16|
    EP0770625A2|1997-05-02|
    US6573056B2|2003-06-03|
    DE19538715A1|1997-04-30|
    DE59609474D1|2002-08-29|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US20080268521A1|2005-09-01|2008-10-30|Novo Nordisk Healthcare A/G|Purification of Coagulation Factor VII Polypeptides|
    US20090043080A1|2004-09-29|2009-02-12|Novo Nordisk Healthcare A/G|Purification of a Bulk of a Factor VII Polypeptide by Fractionated Elution from an Anion-Exchange Material|US3880714A|1973-07-18|1975-04-29|Warner Lambert Co|Diagnostic reagent|
    JPS6353970B2|1981-02-12|1988-10-26|Eisai Co Ltd||
    US4456591A|1981-06-25|1984-06-26|Baxter Travenol Laboratories, Inc.|Therapeutic method for activating factor VII|
    DE3150596A1|1981-12-21|1983-06-30|Boehringer Mannheim Gmbh, 6800 Mannheim|METHOD FOR PRODUCING TISSUE HROMBOPLASTIN|
    US5017556A|1986-11-04|1991-05-21|Genentech, Inc.|Treatment of bleeding disorders using lipid-free tissue factor protein|
    US5118614A|1988-01-18|1992-06-02|Tessek Sdruzeni Praha|Concentrates of coagulation factors ii, vii, ix and x, method of their preparation and use|
    EP0360871B2|1988-03-03|1999-06-30|Nippon Shoji Kabushiki Kaisha|Method for measuring biological activity of antithrombin iii and reagent kit for the measurement|
    FR2632524B1|1988-06-09|1992-03-13|Fondation Nale Transfusion San|PROCESS FOR THE PREPARATION OF A CONCENTRATED FRACTION IN FACTOR VIIA AND ITS APPLICATION AS A MEDICAMENT|
    DE59109032D1|1990-06-28|1998-09-03|Hoechst Ag|Fusion proteins with immunoglobulin components, their production and use|
    US5472850A|1991-04-10|1995-12-05|Oklahoma Medical Research Foundation|Quantitative clotting assay for activated factor VII|
    FR2684999B1|1991-12-16|1995-05-05|Aquitaine Dev Transf Sanguine||
    US5374617A|1992-05-13|1994-12-20|Oklahoma Medical Research Foundation|Treatment of bleeding with modified tissue factor in combination with FVIIa|
    US5348942A|1993-03-12|1994-09-20|Xoma Corporation|Therapeutic uses of bactericidal/permeability increasing protein products|
    DK38293D0|1993-03-31|1993-03-31|Novo Nordisk As|PREPARATION OF PROTEINS|DE19538716A1|1995-10-18|1997-04-24|Behringwerke Ag|Method for quantification of activated coagulation factor VII |
    AT408613B|1998-06-17|2002-01-25|Immuno Ag|PHARMACEUTICAL FACTOR VII PREPARATION|
    DE60040539D1|1999-07-14|2008-11-27|Novo Nordisk Healthcare Ag|USE OF FVIIa OR A TISSUE FACTOR AGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS|
    AU2002351756A1|2001-12-21|2003-07-15|Novo Nordisk Health Care Ag|Liquid composition of factor vii polypeptides|
    DK2283856T3|2002-06-21|2017-11-20|Novo Nordisk Healthcare Ag|Stabilized solid compositions of Factor VIIa polypeptides|
    EP1656158B1|2003-08-14|2016-03-09|Novo Nordisk Health Care AG|Liquid, aqueous pharmaceutical composition of factor vii polypeptides|
    US7897734B2|2003-03-26|2011-03-01|Novo Nordisk Healthcare Ag|Method for the production of proteins|
    EP1611236A1|2003-03-18|2006-01-04|Novo Nordisk Health Care AG|Method for the production of gla-residue containing serine proteases|
    WO2004112828A1|2003-06-25|2004-12-29|Novo Nordisk Health Care Ag|Liquid composition of factor vii polypeptides|
    KR20060015574A|2003-05-23|2006-02-17|노보 노르디스크 헬스 케어 악티엔게젤샤프트|Protein stabilization in solution|
    EP2298287B1|2003-12-19|2018-04-11|Novo Nordisk Health Care AG|Stabilised compositions of factor VII polypeptides|
    CN101006175A|2004-08-17|2007-07-25|Csl百灵有限公司|Modified vitamin k dependent polypeptides|
    KR20130128013A|2004-12-23|2013-11-25|노보 노르디스크 헬스 케어 악티엔게젤샤프트|Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest|
    PL1907540T3|2005-07-22|2013-05-31|Bayer Healthcare Llc|In-solution activation of factor vii|
    WO2007071767A1|2005-12-23|2007-06-28|Novo Nordisk Health Care Ag|Purification of vitamin k-dependent polypeptides using preparative reverse phase chromatography |
    EP1816201A1|2006-02-06|2007-08-08|CSL Behring GmbH|Modified coagulation factor VIIa with extended half-life|
    AU2007236280B2|2006-04-11|2013-07-25|Csl Behring Gmbh|Method of increasing the in vivo recovery of therapeutic polypeptides|
    US7939632B2|2006-06-14|2011-05-10|Csl Behring Gmbh|Proteolytically cleavable fusion proteins with high molar specific activity|
    EP2097096B1|2006-12-22|2017-05-31|CSL Behring GmbH|Modified coagulation factors with prolonged in vivo half-life|
    法律状态:
    2003-05-14| STCF| Information on status: patent grant|Free format text: PATENTED CASE |
    2004-10-25| AS| Assignment|Owner name: ZLB BEHRING GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AVENTIS BEHRING GMBH;REEL/FRAME:015286/0411 Effective date: 20040624 |
    2006-11-13| FPAY| Fee payment|Year of fee payment: 4 |
    2007-09-10| AS| Assignment|Owner name: CSL BEHRING GMBH, GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:ZLB BEHRING GMBH;REEL/FRAME:019825/0880 Effective date: 20061201 |
    2010-10-29| FPAY| Fee payment|Year of fee payment: 8 |
    2014-11-05| FPAY| Fee payment|Year of fee payment: 12 |
    优先权:
    申请号 | 申请日 | 专利标题
    DE19538715||1995-10-18||
    DE19538715A|DE19538715A1|1995-10-18|1995-10-18|Process for cleaning factor VII and activated factor VII|
    DE19538715.5||1995-10-18||
    US73157796A| true| 1996-10-16|1996-10-16||
    US09/768,294|US6573056B2|1995-10-18|2001-01-25|Process for purifying factor VII and activated factor VII|US09/768,294| US6573056B2|1995-10-18|2001-01-25|Process for purifying factor VII and activated factor VII|
    [返回顶部]